For instance, TET2 mutation had no prognostic significance in AML according to Gaidzik's study, but its unfavorable prognostic impact on AML patients with intermediate‐risk cytogenetics (IR‐AML) was reported by Chou.12, 13. This evidence concerns the gene TET2 and acute myeloid leukemia.